Condition: Diffuse Large B Cell Lymphoma · Sponsor: Affiliated Hospital of Nantong University
This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and orelabrutinib in this population. The primary endpoint is CR rate after induction therapy.
This description comes directly from the study's public registry record.
Wenyu Shi · +86 13515203737 · shiwenyu@hotmail.com
Always discuss trial participation with your own doctor first.
| Affiliated hospital of Nantong University | Nantong, Jiangsu, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06530511